Gross payment volume was $1 billion better than expected. The company also raised its guidance for full-year 2017, now expecting revenues of $677 million to $680 million. Shares of Gilead Sciences fell slightly in choppy trade after the bell. The company reported adjusted quarterly earnings of $2.75 per share, which missed Wall Street expectations of $2.86 a share. Gilead barely beat on revenues, reporting $7.50 billion compared with estimates of $7.45 billion. It's Hepatitis C drug sales missed expectations, as it saw revenues of $3.33 billion, versus analysts' estimates of closer to $3.7 billion.